Considering its several anti-tumour effects, including the activation of immune effector cells
eventually targeting leukaemia stem cells, there has been a greater interest in the revival of
IFN-α as a combination therapy with TKIs in order to increase the proportion of patients aiming
at treatment-free remission. Interestingly, prior treatment with IFN-α in patients
discontinuing imatinib was identified as a prognostic factor for maintenance of a major
molecular response and treatment-free remission success. With new pegylated formulations,
the undesirable and hampering side effects of IFN-α may be improved, along with its efficacy,
and an older therapeutic option may regain an important role in complementing the
molecular-specific approach of TKIs with potent anti-leukaemia immunosurveillance.
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES